Why did Phase 1/2 FTO solid tumour clinical trial ($8.0 million) get the nod for the base case over Cardio-protection Phase 2b clinical trial in breast cancer patients ($7.5 million)?
I understand the FTO opportunity was discovered earlier, but recent commentary suggests cardio-protection is easier to recruit for and quicker to market all going well.
I hope the full case gets funded, and I think it will. I am taking up my allocation.
Ann: Race Oncology Share Purchase Plan Opens, page-401
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.110(7.10%) |
Mkt cap ! $279.5M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.75 | $1.61 | $465.4K | 277.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 1033 | 2 |
View Market Depth
| Last trade - 12.45pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.66 |
Change
0.110 ( 8.28 %) |
||||
| Open | High | Low | Volume | ||
| $1.64 | $1.73 | $1.63 | 22127 | ||
| Last updated 12.45pm 14/05/2024 ? | |||||
| RAC (ASX) Chart |